An approach to acute severe ulcerative colitis

References

• Lynch RW, Lowe D, Protheroe A, et al. Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit. Aliment Pharmacol Ther. 2013;38:935–945.
   PubMed Web of Science ®Google Scholar
• Rice-Oxley JM, Truelove SC. Ulcerative colitis course and prognosis. Lancet. 1950;255:663–666.
   Google Scholar
• Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1963;4:299–315.
   PubMed Web of Science ®Google Scholar
• Solberg IC, Lygren I, Jahnsen J, et al. IBSEN study group. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431–440.
   PubMed Web of Science ®Google Scholar
• Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010;4:431–437.
   PubMed Web of Science ®Google Scholar
• Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomized trial. Lancet Gastroenterol Hepatol. 2016;1:15–24.
   PubMed Web of Science ®Google Scholar
• Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis. 2008;40:821–826.
   PubMedGoogle Scholar
• Kaplan GG, Seow CH, Ghosh S, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol. 2012;107:1879–1887.
   PubMed Web of Science ®Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al. European Crohn’s and colitis organisation [ECCO]. third european evidence based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo anal pouch disorders. J Crohns Colitis. 2017;1:649–670.
   Google Scholar
• Xie T, Zhang T, Ding C, et al. ulcerative colitis endoscopic index of severity (UCEIS) versus mayo endoscopic score (MES) in guiding the need for colectomy in patients with acute severe colitis. Gastroenterol Rep (Oxf). 2017;6:38–44.
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J. 1954;2:375–378.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–1725.
   PubMed Web of Science ®Google Scholar
• Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004;19:1079–1087.
   PubMed Web of Science ®Google Scholar
• Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905–910.
   PubMed Web of Science ®Google Scholar
• Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol. 1998;10:831–835.
   PubMed Web of Science ®Google Scholar
• Seo M, Okada M, Yao T, et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992;87:971–976.
   PubMed Web of Science ®Google Scholar
• Bernardo S, Fernandes SR, Gonçalves AR, et al. Predicting the course of disease in hospitalized patients with acute severe ulcerative colitis. Inflamm Bowel Dis. 2019;25:541–546.
   PubMed Web of Science ®Google Scholar
• Lynch R, Churchhouse A, Protheroe A, et al. Predicting outcome in acute severe ulcerative colitis: comparison of the Travvis and Ho scores using UK IBD audit data. Aliment Pharmacol Ther. 2016;43:1132–1141.
   PubMed Web of Science ®Google Scholar
• Moore A, Bressler B. Acute severe ulcerative colitis: the oxford criteria no longer predict in-hospital colectomy rates. Dig Dis Sci. 2019 May 15. [Epub ahead of print].
   Google Scholar
• Chen JH, Andrews JM, Kariyawasam V, et al. IBD sydney organisation and the Australian inflammatory bowel diseases consensus working group. Review: acute severe ulcerative colitis – evidence-based consensus statements. Aliment Pharmacol Ther. 2016;44:127–144.
   PubMedGoogle Scholar
• Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int. 2000;13:313–326.
   PubMed Web of Science ®Google Scholar
• Qumseya BJ, Ananthakrishnan AN, Skaros S, et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis. 2011;17:77–83.
   PubMed Web of Science ®Google Scholar
• Jakobovits SL, Travis SP. Management of acute severe colitis. Br Med Bull. 2006;75–76:131–144.
   PubMed Web of Science ®Google Scholar
• Mortensen C, Caspersen S, Christensen NL, et al. Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals. Inflamm Bowel Dis. 2008;14:347–352.
   PubMedGoogle Scholar
• Beswick L, Rosella O, Rosella G, et al. Exploration of Predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study. J Crohns Colitis. 2018;12:289–297.
   PubMed Web of Science ®Google Scholar
• Choy MC, Seah D, Gorelik A, et al. Predicting response after infliximab salvage in acute severe ulcerative colitis. J Gastroenterol Hepatol. 2018;33:1347–1352.
   PubMed Web of Science ®Google Scholar
• Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104:673–678.
   PubMed Web of Science ®Google Scholar
• Jain S, Kedia S, Bopanna S, et al. Faecal calprotectin and UCEIS predict short- term outcomes in acute severe colitis: prospective cohort study. J Crohns Colitis. 2017;11:1309–1316.
   PubMed Web of Science ®Google Scholar
• Wang Y, Atreja A, Wu X, et al. Similar outcomes of IBD in patients with Clostridium difficile infection detected by ELISA or PCR assay. Dig Dis Sci. 2013;58:2308–2313.
   PubMed Web of Science ®Google Scholar
• Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med. 2015;175:1792–1801.
   PubMed Web of Science ®Google Scholar
• Deshpande A, Pasupuleti V, Patel P, et al. Repeat stool testing for Clostridium difficile using enzyme immunoassay in patients with inflammatory bowel disease increases diagnostic yield. Curr Med Res Opin. 2012;28:1553–1560.
   PubMed Web of Science ®Google Scholar
• Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:345–351.
   PubMed Web of Science ®Google Scholar
• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of america (IDSA) and society for healthcare epidemiology of America (SHEA). Clin Infect Dis. 2018;66:987–994.
   PubMed Web of Science ®Google Scholar
• Aichinger E, Schleck CD, Harmsen WS, et al. Nonutility of repeat laboratory testing for detection of Clostridium difficile by use of PCR or enzyme immunoassay. J Clin Microbiol. 2008;46:3795–3797.
   PubMed Web of Science ®Google Scholar
• Chew CN, Nolan DJ, Jewell DP. Small bowel gas in severe ulcerative colitis. Gut. 1991;32:1535–1537.
   PubMed Web of Science ®Google Scholar
• da Luz Moreira A, Vogel JD, Baker M, et al. Does CT influence the decision to perform colectomy in patients with severe ulcerative colitis? J Gastrointest Surg. 2009;13:504–507.
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Mandalia AB, Dauer RM, et al. Predictive factors for clinically actionable computed tomography findings in inflammatory bowel disease patients seen in the emergency department with acute gastrointestinal symptoms. J Crohns Colitis. 2014;8:504–512.
   PubMed Web of Science ®Google Scholar
• Hafeez R, Punwani S, Pendse D, et al. Derivation of a T2-weighted MRI total colonic inflammation score (TCIS) for assessment of patients with severe acute inflammatory colitis-a preliminary study. Eur Radiol. 2011;21:366–377.
   PubMed Web of Science ®Google Scholar
• Madsen SM, Thomsen HS, Munkholm P, et al. Active Crohn’s disease and ulcerative colitis evaluated by low-field magnetic resonance imaging. Scand J Gastroenterol. 1998;33:1193–1200.
   PubMed Web of Science ®Google Scholar
• Nozue T, Kobayashi A, Takagi Y, et al. Assessment of disease activity and extent by magnetic resonance imaging in ulcerative colitis. Pediatr Int. 2000;42:285–288.
   PubMed Web of Science ®Google Scholar
• Sardanelli F, de Cicco E, Renzetti P, et al. Double-contrast magnetic resonance examination of ulcerative colitis. Eur Radiol. 1999;9:875–879.
   PubMed Web of Science ®Google Scholar
• Allocca M, Fiorino G, Bonovas S, et al. Accuracy of humanitas ultrasound criteria in assessing disease activity and severity in ulcerative colitis: a prospective study. J Crohns Colitis. 2018;12:1385–1391.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. European Crohn’s and colitis organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current Management. J Crohns Colitis. 2017;11:769–784.
   PubMed Web of Science ®Google Scholar
• Criscuoli V, Casà A, Orlando A, et al. Severe acute colitis associated with CMV: a prevalence study. Dig Liver Dis. 2004;36:818–820.
   PubMedGoogle Scholar
• Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol. 2006;101:2857–2865.
   PubMed Web of Science ®Google Scholar
• Maher MM, Nassar MI. Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease. Dig Dis Sci. 2009;54:2456–2462.
   PubMed Web of Science ®Google Scholar
• Cottone M, Pietrosi G, Martorana G, et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn’s colitis. Am J Gastroenterol. 2001;96:773–775.
   PubMed Web of Science ®Google Scholar
• Delvincourt M, Lopez A, Pillet S, et al. The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:712–720.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Magro F, Abreu C, et al. European Crohn’s and colitis organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443–468.
   PubMed Web of Science ®Google Scholar
• Pola S, Feagan BG, Fahmy M, et al. Observer agreement and construct validity in central endoscopic assessment of disease activity in ulcerative colitis. Gastroenterology. 2013;144:S–763.
   Web of Science ®Google Scholar
• Corte C, Fernandopulle N, Catuneanu AM, et al. Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. J Crohns Colitis. 2015;9:376–381.
   PubMed Web of Science ®Google Scholar
• García Rodríguez LA, González-Pérez A, Johansson S, et al. Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther. 2005;22:309–315.
   PubMed Web of Science ®Google Scholar
• Felder JB, Korelitz BI, Rajapakse R, et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2000;95:1949–1954.
   PubMed Web of Science ®Google Scholar
• Kefalakes H, Stylianides TJ, Amanakis G, et al. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur J Clin Pharmacol. 2009;65:963–970.
   PubMed Web of Science ®Google Scholar
• Gan SI, Beck PL. A new look at toxic megacolon: an up-date and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol. 2003;98:2363–2371.
   PubMed Web of Science ®Google Scholar
• González-Huix F, Fernández-Bañares F, Esteve-Comas M, et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol. 1993;88:227–232.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014;146:835–848.
   PubMed Web of Science ®Google Scholar
• Chu T, Grainge M, Card T. The risk of venous thromboembolism during and after hospitalization in patients with inflammatory bowel disease activity. Aliment Pharmacol Ther. 2018;48:1099–1108.
   PubMed Web of Science ®Google Scholar
• Danese S, Papa A, Saibeni S, et al. Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am J Gastroenterol. 2007;102:174–186.
   PubMed Web of Science ®Google Scholar
• Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1545–1553.
   PubMed Web of Science ®Google Scholar
• Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211–222.
   PubMed Web of Science ®Google Scholar
• Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–110.
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ. 1955;2:1041–1048.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology. 2001;120:1323–1329.
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–1845.
   PubMed Web of Science ®Google Scholar
• Van Assche G, D’Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025–1031.
   PubMed Web of Science ®Google Scholar
• Patel P, Yarur A, Dalal S, et al. Clinical response and complications are not associated with drug levels in patients with severe ulcerative colitis on IV cyclosporine induction therapy. Inflamm Bowel Dis. 2018;24:1291–1297.
   PubMed Web of Science ®Google Scholar
• Whaley KG, Rosen MJ. Contemporary medical management of acute severe ulcerative colitis. Inflamm Bowel Dis. 2019;25:56–66.
   PubMed Web of Science ®Google Scholar
• Sternthal MB, Murphy SJ, George J, et al. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol. 2008;103:937–943.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66:839–851.
   PubMed Web of Science ®Google Scholar
• Ordas I, Domenech E, Manosa M, et al. Long-term efficacy and safety of cyclosporine in a cohort of steroid-refractory acute severe ulcerative colitis patients from the ENEIDA registry (1989–2013): a nationwide multicenter study. Am J Gastroenterol. 2017;112:1709–1718.
   PubMed Web of Science ®Google Scholar
• Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2012;18:803–808.
   PubMed Web of Science ®Google Scholar
• Komaki Y, Komaki F, Ido A, et al. Efficacy and safety of tacrolimus therapy for active ulcerative colitis; a systematic review and meta-analysis. J Crohns Colitis. 2016;10:484–494.
   PubMed Web of Science ®Google Scholar
• Thomas CW, Myhre GM, Tschumper R, et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther. 2005;312:537–545.
   PubMed Web of Science ®Google Scholar
• Warner B, Johnston E, Arenas-Hernandez M, et al. A practical guide to thiopurine prescribing and monitoring in IBD. Frontline Gastroenterol. 2018;9:10–15.
   PubMed Web of Science ®Google Scholar
• Kedia S, Ahuja V, Tandon R. Management of acute severe ulcerative colitis. World J Gastrointest Pathophysiol. 2014;5:579–588.
   PubMedGoogle Scholar
• Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:760–765.
   PubMed Web of Science ®Google Scholar
• Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007;5:209–214.
   PubMed Web of Science ®Google Scholar
• Friedman AB, Brown SJ, Bampton P, et al. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA study). Aliment Pharmacol Ther. 2018;47:1092–1102.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122:904–915.
   PubMed Web of Science ®Google Scholar
• Blaker PA, Arenas-Hernandez M, Smith MA, et al. Mechanism of allopurinol induced TPMT inhibition. Biochem Pharmacol. 2013;86:539–547.
   PubMed Web of Science ®Google Scholar
• Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864–875.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. GEMINI 1 study group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. GEMINI 2 study group. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.
   PubMed Web of Science ®Google Scholar
• Christensen B, Gibson PR, Micic D, et al. Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease. Clin Gastroenterol Hepatol. 2019;17:486–493.
   PubMed Web of Science ®Google Scholar
• Pellet G, Stefanescu C, Carbonnel F, et al. Groupe d’Etude thérapeutique des affections inflammatoires du tube digestif. Efficacy and safety of induction therapy with calcineurin inhibitors in combination with vedolizumab in patients with refractory ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17:494–501.
   PubMed Web of Science ®Google Scholar
• Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26:411–419.
   PubMed Web of Science ®Google Scholar
• Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–1811.
   PubMed Web of Science ®Google Scholar
• Sjoberg M, Magnuson A, Bjork J, et al. Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Aliment Pharmacol Ther. 2013;38:377–387.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
   PubMed Web of Science ®Google Scholar
• Reich KM, Chang HJ, Rezaie A, et al. The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. Aliment Pharmacol Ther. 2014;40:629–638.
   PubMed Web of Science ®Google Scholar
• Mazzola G, Macaluso FS, Adamoli L, et al. Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. J Infect. 2017;74:433–441.
   PubMed Web of Science ®Google Scholar
• Brandse JF, Mathot RA, van der Kleij D, et al. Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14:251–258. e1–2.
   PubMed Web of Science ®Google Scholar
• Brandse JF, van Den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149:350–355.
   PubMed Web of Science ®Google Scholar
• Gibson DJ, Heetun ZS, Redmond CE, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:330–335.
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Jain A, Sussman DA, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65:249–255.
   PubMed Web of Science ®Google Scholar
• Fasanmade AA, Adedokun OJ, Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48:297–308.
   PubMed Web of Science ®Google Scholar
• Hindryckx P, Jairath V, D’Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13:654–664.
   PubMed Web of Science ®Google Scholar
• An YK, Chen CY, White LS, et al. Accelerated dosing of infliximab induction and endoscopic mucosal healing in patients with acute severe ulcerative colitis. J Gastroenterol Hepatol. 2017;32:121–154.
   Web of Science ®Google Scholar
• Choy MC, Seah D, Gorelik A, et al. Comparison of accelerated infliximab induction vs standard induction treatment in acute severe ulcerative colitis. Gastroenterology. 2016;150:S803.
   PubMed Web of Science ®Google Scholar
• Nalagatla N, Falloon K, Tran G, et al. Effect of accelerated infliximab induction on short-and long-term outcomes of acute severe ulcerative Colitis: A retrospective multicenter study and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:502–509.
   PubMed Web of Science ®Google Scholar
• Herfath H, Rogler G, Higgins P. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? Clin Gastroenterol Hepatol. 2015;13:336–338.
   PubMed Web of Science ®Google Scholar
• Chao CY, Khoury A, Aruljothy A, et al. High-dose infliximab rescue therapy for hospitalized acute severe ulcerative colitis does not improve colectomy-free survival. Dig Dis Sci. 2019;64:518–523.
   PubMed Web of Science ®Google Scholar
• Kaniewska M, Moniuszko A, Grazyna R. The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis. Prz Gastroenterol. 2017;12:169–174.
   PubMed Web of Science ®Google Scholar
• Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant. 2006;21(Suppl. 5):v4–8.
   PubMed Web of Science ®Google Scholar
• Morrow T, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthc. 2004;1:24–29.
   PubMedGoogle Scholar
• Sebastian S, Myers S, Argyriou K, et al. Infliximab induction regimens in steroid‐refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis. Aliment Pharmacol Ther. 2019;50:675–683.
   PubMed Web of Science ®Google Scholar
• Laharie D, Bourreille A, Branche J, et al. Groupe d’Etudes thérapeutiques des affections inflammatoires digestive. Long-term outcome of patients with steroid- refractory acute severe UC treated with ciclosporin or infliximab. Gut. 2018;67:237–243.
   PubMed Web of Science ®Google Scholar
• Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43:482–513.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Kawamura H, Nishikawa T, et al. Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study. Clin Exp Gastroenterol. 2017;10:249–258.
   PubMed Web of Science ®Google Scholar
• Turner D, Travis SP, Griffiths AM, et al. European Crohn’s and colitis organization; Porto IBD working group, European society of pediatric Gastroenterology, Hepatology, and nutrition. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD working group of ESPGHAN. Am J Gastroenterol. 2011;106:574–588.
   PubMed Web of Science ®Google Scholar
• Weisshof R, Ollech JE, El Jurdi K, et al. Ciclosporin therapy after infliximab failure in hospitalized patients with acute severe colitis is effective and safe. J Crohns Colitis. 2019;13:1105–1110.
   PubMedGoogle Scholar
• Protic M, Seibold F, Schoepfer A, et al. The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. J Crohns Colitis. 2014;8:1427–1437.
   PubMed Web of Science ®Google Scholar
• Chapman CG, Bochenek A, Stein AC, et al. Use of serum infliximab level prior to cyclosporine salvage therapy in severe ulcerative colitis. ACG Case Rep J. 2014;1:148–150.
   PubMedGoogle Scholar
• Sandborn WJ, Su C, Sands BE, et al. OCTAVE induction 1, OCTAVE induction 2, and OCTAVE sustain investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.
   PubMed Web of Science ®Google Scholar
• Hanauer S, Panaccione R, Danese S, et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17:139–147.
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Steiner CA, Regal RE, et al. Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17:988–990.
   PubMed Web of Science ®Google Scholar
• Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39:660–671.
   PubMed Web of Science ®Google Scholar
• Fornaro R, Caratto M, Barbruni G, et al. Surgical and medical treatment in patients with acute severe ulcerative colitis. J Dig Dis. 2015;16:558–567.
   PubMed Web of Science ®Google Scholar
• Ordás I, Domènech E, Mañosa M, et al. ENEIDA registry of GETECCU. Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: nationwide multicenter study of the GETECCU ENEIDA registry. Am J Gastroenterol. 2018;113:1009–1016.
   PubMed Web of Science ®Google Scholar
• Gu J, Stocchi L, Ashburn J, et al. Total abdominal colectomy vs. restorative total proctocolectomy as the initial approach to medically refractory ulcerative colitis. Int J Colorectal Dis. 2017;32:1215–1222.
   PubMed Web of Science ®Google Scholar
• Andersson P, Söderholm JD. Surgery in ulcerative colitis: indication and timing. Dig Dis. 2009;27:335–340.
   PubMed Web of Science ®Google Scholar
• Holubar SD, Larson DW, Dozois EJ, et al. Minimally invasive subtotal colectomy and ileal pouch-anal anastomosis for fulminant ulcerative colitis: a reasonable approach? Dis Colon Rectum. 2009;52:187–192.
   PubMed Web of Science ®Google Scholar
• Buchs NC, Bloemendaal ALA, Wood CPJ, et al. Subtotal colectomy for ulcerative colitis: lessons learned from a tertiary centre. Colorectal Dis. 2017;19:O153–61.
   PubMed Web of Science ®Google Scholar
• Oresland T, Bemelman WA, Sampietro GM, et al. European evidence based consensus on surgery for ulcerative colitis. J Crohns Colitis. 2015;9:4–25.
   PubMed Web of Science ®Google Scholar
• Anderson M, Lynn P, Aydinli HH, et al. Early experience with urgent robotic subtotal colectomy for severe acute ulcerative colitis has comparable perioperative outcomes to laparoscopic surgery. J Robot Surg. 2019 May 10. [Epub ahead of print].
   PubMedGoogle Scholar
• Kornbluth A, Sachar DB. Practice parameters committee of the American college of Gastroenterology. Ulcerative colitis practice guidelines in adults: American college of Gastroenterology, practice parameters committee. Am J Gastroenterol. 2010;105:501–523.
   PubMed Web of Science ®Google Scholar
• Gross V, Bar-Meir S, Lavy A, et al. International budesonide foam study group. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther. 2006;23:303–312.
   PubMed Web of Science ®Google Scholar
• Zeng J, Lv L, Mei ZC. Budesonide foam for mild to moderate distal ulcerative colitis: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32:558–566.
   PubMed Web of Science ®Google Scholar
• Christophi GP, Rengarajan A, Ciorba MA. Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach. Clin Exp Gastroenterol. 2016;9:125–130.
   PubMed Web of Science ®Google Scholar
• Dickinson RJ, O’Connor HJ, Pinder I, et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut. 1985;26:1380–1384.
   PubMed Web of Science ®Google Scholar
• Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut. 1986;27:1210–1212.
   PubMed Web of Science ®Google Scholar
• Ledder O, Turner D. Antibiotics in IBD: still a role in the biological era? Inflamm Bowel Dis. 2018;24:1676–1688.
   PubMed Web of Science ®Google Scholar